Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 701–800 of 1,015
Hajizadeh, F., Moghadaszadeh Ardebili, S., Baghi Moornani, M., Masjedi, A., Atyabi, F., Kiani, M., Namdar, A., Karpisheh, V., Izadi, S., Baradaran, B., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173235 · Cited by 76
Conway, J. R. W., Warren, S. C., Herrmann, D., Murphy, K. J., Cazet, A., Vennin, C., Shearer, R. F., Killen, M. J., Magenau, A., Mélénec, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.038 · Cited by 76
Sun, X., He, Z., Guo, L., Wang, C., Lin, C., Ye, L., Wang, X., Li, Y., Yang, M., Liu, S., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01932-8 · Cited by 89
Sun, L., Li, G., Chen, X., Chen, Y., Jin, C., Ji, L., & Chao, H. (2015) · Scientific Reports · doi:10.1038/srep14837 · Cited by 77
Grist, S. M., Nasseri, S. S., Laplatine, L., Schmok, J. C., Yao, D. R., Hua, J., Chrostowski, L., & Cheung, K. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-54001-8 · Cited by 79
Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery
Son, S., Rao, N. V., Ko, H., Shin, S., Jeon, J., Han, H. S., Nguyen, V. Q., Thambi, T., Suh, Y. D., & Park, J. H. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.11.048 · Cited by 75
Une, N., Takano-Kasuya, M., Kitamura, N., Ohta, M., Inose, T., Kato, C., Nishimura, R., Tada, H., Miyagi, S., Ishida, T., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01503-z · Cited by 82
Ma, M., Kong, X., Weng, M., Zhang, M., Qin, Y., Gong, W., Zhang, W., & Quan, Z. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22215 · Cited by 72
Responsive triggering systems for delivery in chronic wound healing
Morey, M., & Pandit, A. S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.02.008 · Cited by 77
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 80
Peixoto, A., Fernandes, E., Gaiteiro, C., Lima, L., Azevedo, R., Soares, J., Cotton, S., Parreira, B., Neves, M., Amaro, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11257 · Cited by 73
Zheng, L., Wang, B., Sun, Y., Dai, B., Fu, Y., Zhang, Y., Wang, Y., Yang, Z., Sun, Z., Zhuang, S., et al. (2021) · ACS Sensors · doi:10.1021/acssensors.0c01846 · Cited by 78
Hypoxia signalling manipulation for bone regeneration
Drager, J., Harvey, E. J., & Barralet, J. E. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.4 · Cited by 77
Lawrence, Y. R., Vikram, B., Dignam, J. J., Chakravarti, A., Machtay, M. X., Freidlin, B., Takebe, N., Curran, W. J., Bentzen, S. M., Okunieff, P. G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs472 · Cited by 74
Magnetic resonance imaging in precision radiation therapy for lung cancer
Bainbridge, H., Salem, A., Tijssen, R. H. N., Dubec, M. J., Wetscherek, A., van Es, C. A., Belderbos, J. S. A., Finn, C. F., & McDonald, F. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.02 · Cited by 74
Li, Y., Wang, M., Zhi, P., You, J., & Gao, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23187 · Cited by 79
Nucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 81
Zegers, C. M. L., van Elmpt, W., Szardenings, K., Kolb, H. C., Waxman, A., Subramaniam, R. M., Moon, D. H., Brunetti, J. C., Srinivas, S. M., Lambin, P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3100-z · Cited by 72
Hu, D., Pan, M., Yu, Y., Sun, A., Shi, K., Qu, Y., & Qian, Z. (2020) · View · doi:10.1002/viw2.6 · Cited by 76
Biomineralized Biohybrid Algae for Tumor Hypoxia Modulation and Cascade Radio-Photodynamic Therapy
Li, W., Zhong, D., Hua, S., Du, Z., & Zhou, M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14400 · Cited by 72
Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment
Ye, Y., Zhao, Y., Sun, Y., & Cao, J. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s362759 · Cited by 76
Cai, J., Shen, Q., Wu, Y., Hu, J., Pan, D., Wu, Y., & Geng, B. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411064 · Cited by 75
Tumor‐Targeting of EGFR Inhibitors by Hypoxia‐Mediated Activation
Karnthaler‐Benbakka, C., Groza, D., Kryeziu, K., Pichler, V., Roller, A., Berger, W., Heffeter, P., & Kowol, C. R. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403936 · Cited by 72
Gan, R., & Li, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150916698 · Cited by 80
New use of metals as nanosized radioenhancers.
Pottier, A., Borghi, E., & Lévy, L. (2014) · PubMed · Cited by 72
Shi, S., Rao, Q., Zhang, C., Zhang, X., Qin, Y., & Niu, Z. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.001 · Cited by 72
Nguyen, T. D., Song, M. S., Ly, N. H., Lee, S. Y., & Joo, S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812677 · Cited by 74
Xie, Z., Guo, W.-W., Guo, N., Huang-Fu, M.-Y., Liu, H., Lin, M., Xu, W., Chen, J., Wang, T., Wei, Q., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.03.013 · Cited by 76
Arshad, M., Thornton, A., Lu, H., Tam, H., Wallitt, K. L., Rodgers, N., Scarsbrook, A. F., McDermott, G. M., Cook, G., Landau, D., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4139-4 · Cited by 76
Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity
Qian, J., & Rankin, E. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_3 · Cited by 75
Zhou, L., Wang, T., Bai, Y., Li, Y., Qiu, J., Yu, W. H., & Zhang, S. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111964 · Cited by 71
Zhang, T., Gong, Y., Meng, H., Li, C., & Xue, L. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00862-0 · Cited by 81
Tumour oxygenation: implications for breast cancer prognosis
Rundqvist, H., & Johnson, R. S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12091 · Cited by 81
Fan, L., Sun, G., Ma, T., Zhong, F., Yu, L., Li, X., & Wei, W. (2013) · Journal of Pineal Research · doi:10.1111/jpi.12061 · Cited by 75
Masaki, Y., Shimizu, Y., Yoshioka, T., Tanaka, Y., Nishijima, K., Zhao, S., Higashino, K., Sakamoto, S. X., Numata, Y., Yamaguchi, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep16802 · Cited by 81
Obesity and melanoma: could fat be fueling malignancy?
Clement, E., Lazar, I., Muller, C., & Nieto, L. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12584 · Cited by 71
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides
Bonnet, M., Hong, C. R., Wong, W. W., Liew, L. P., Shome, A., Wang, J., Gu, Y., Stevenson, R. J., Qi, W., Anderson, R. F., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01678 · Cited by 75
Self-citationLi, J., Xue, Y., Tian, J., Liu, Z., Zhuang, A., Gu, P., Zhou, H., Zhang, W., & Fan, X. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116119 · Cited by 70
Liu, H., Jiang, W., Wang, Q., Hang, L., Wang, Y., & Wang, Y. (2019) · Biomaterials Science · doi:10.1039/c9bm00634f · Cited by 73
Delivery of therapeutic oligonucleotides in nanoscale
Wu, L., Zhou, W., Lin, L., Chen, A., Feng, J. C., Qu, X., Zhang, H., & Yue, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.038 · Cited by 83
Liu, J., Cabral, H., Song, B., Aoki, I., Chen, Z., Nishiyama, N., Huang, Y., Kataoka, K., & Mi, P. (2021) · ACS Nano · doi:10.1021/acsnano.1c04263 · Cited by 75
A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis
Tian, H., Zhou, L., Wang, Y., Nice, E. C., Huang, C., & Zhang, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.022 · Cited by 70
Conley, S. J., Baker, T. L., Burnett, J., Theisen, R., Lazarus, D. D., Peters, C. G., Clouthier, S. G., Eliasof, S. D., & Wicha, M. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3349-8 · Cited by 71
Autophagy, a double-edged sword in anti-angiogenesis therapy
Liu, J., Fan, L., Wang, H., & Sun, G. (2015) · Medical Oncology · doi:10.1007/s12032-015-0721-9 · Cited by 75
Yang, Y. P., Chao, Y., Liu, J., Dong, Z., He, W., Zhang, R., Yang, K., Chen, M., & Liu, Z. (2017) · NPG Asia Materials · doi:10.1038/am.2016.205 · Cited by 70
Mesoporous silica nanoparticles in recent photodynamic therapy applications
Bayır, S., Barras, A., Boukherroub, R., Szunerits, S., Raehm, L., Richeter, S., & Durand, J. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00143j · Cited by 74
Biologically activatable azobenzene polymers targeted at drug delivery and imaging applications
Eom, T., Yoo, W., Kim, S., & Khan, A. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.020 · Cited by 75
HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
Jarman, E. J., Ward, C., Turnbull, A., Martínez-Pérez, C., Meehan, J., Xintaropoulou, C., Sims, A. H., & Langdon, S. P. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1097-0 · Cited by 80
ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma
Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02460-1 · Cited by 69
“The HIF heterodimers bind to conserved hypoxia response elements (HREs) within regulatory regions of target genes to activate transcription of hundreds of genes critical for the adaptation to hypoxia, and for tumor progression, such as those promoting aerobic glycolysis, angiogenesis, and metastasis [6, 7].”
BackgroundMeng, L., Cheng, Y., Gan, S., Zhang, Z., Tong, X., Xu, L., Jiang, X., Zhu, Y., Wu, J., Yuan, A., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00808 · Cited by 69
Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions
Zhang, X., Ding, K., Wang, J., Li, X., & Zhao, P. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.063 · Cited by 73
Zuo, H. X., Jin, Y., Wang, Z., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112835 · Cited by 70
Re-engineering natural products to engage new biological targets
Motika, S. E., & Hergenrother, P. J. (2020) · Natural Product Reports · doi:10.1039/d0np00059k · Cited by 69
López-Codony, V., & Tavassoli, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101017 · Cited by 77
Fornari, F., Giovannini, C., Piscaglia, F., & Gramantieri, L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s285726 · Cited by 75
Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy
Esposito, F., Giuffrida, R., Raciti, G., Puglisi, C., & Forte, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910689 · Cited by 76
Dash, B. S., Lin, Y.-J., & Chen, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c19152 · Cited by 73
Prognostic Value of HIFs Expression in Head and Neck Cancer: A Systematic Review
Gong, L., Zhang, W., Zhou, J., Lu, J., Xiong, H., Xueli, S., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075094 · Cited by 73
A Probe for the Detection of Hypoxic Cancer Cells
Luo, S., Zou, R., Wu, J., & Landry, M. P. (2017) · ACS Sensors · doi:10.1021/acssensors.7b00171 · Cited by 69
Recent Progress in the Design of Hypoxia‐Specific Nano Drug Delivery Systems for Cancer Therapy
Sahu, A., Choi, W. I., & Tae, G. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800026 · Cited by 68
Tan, Q., Saggar, J. K., Yu, M., Wang, M., & Tannock, I. F. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000131 · Cited by 73
He, X., Peng, C., Qiang, S., Xiong, L., Zhao, Z., Wang, Z., Kwok, R. T. K., Lam, J. W. Y., Ma, N., & Tang, B. Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119834 · Cited by 68
Exosomes: A Potential Therapeutic Tool Targeting Communications between Tumor Cells and Macrophages
Guo, W., Li, Y., Pang, W., & Shen, H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.003 · Cited by 75
Neitzel, C., Demuth, P., Wittmann, S., & Fahrer, J. (2020) · Cancers · doi:10.3390/cancers12071731 · Cited by 74
Sarkar, S., Lee, H., Ryu, H. G., Singha, S., Lee, Y. M., Reo, Y. J., Jun, Y. W., Kim, K. H., Kim, W. J., & Ahn, K. H. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01989 · Cited by 69
Ding, L., Wu, Y., Wu, M., Zhao, Q., Li, H., Liu, J., Liu, X., Zhang, X., & Zeng, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c19096 · Cited by 69
Chouke, P. B., Potbhare, A. K., Meshram, N. P., Rai, M. M., Dadure, K. M., Chaudhary, K., Rai, A. R., Desimone, M. F., Chaudhary, R. G., & Masram, D. T. (2022) · ACS Omega · doi:10.1021/acsomega.1c06544 · Cited by 67
Jiang, H., Li, A. M., & Ye, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004978 · Cited by 73
Hypoxia-induced ROS aggravate tumor progression through HIF-1α-SERPINE1 signaling in glioblastoma
Zhang, L., Cao, Y., Guo, X., Wang, X., Han, X., Kanwore, K., Hong, X., Zhou, H., & Gao, D. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200269 · Cited by 75
Zhang, S., Rodriguez, L. M. D. L., Li, F. F., & Brimble, M. A. (2023) · Chemical Science · doi:10.1039/d3sc02543h · Cited by 75
Hu, J., Valckenborgh, E. V., Menu, E., Bruyne, E. D., & Vanderkerken, K. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.008961 · Cited by 74
Yıldırım, A., Blum, N. T., & Goodwin, A. P. (2019) · Theranostics · doi:10.7150/thno.32424 · Cited by 75
Microbial amphiphiles: a class of promising new-generation anticancer agents
Dey, G., Bharti, R., Sen, R., & Mandal, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.006 · Cited by 67
A Review on the Special Radiotherapy Techniques of Colorectal Cancer
Tam, S. Y., & Wu, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00208 · Cited by 67
Ihsanullah, K. M., Kumar, B. N., Zhao, Y., Hassan, M., Liu, Y., Wang, L., Liu, H., & Jiang, W. J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119982 · Cited by 69
Hypoxia and cancer related pathology
Xiong, Q., Liu, B., Ding, M., Zhou, J., Yang, C., & Chen, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.002 · Cited by 72
Recent achievements of bioluminescence imaging based on firefly luciferin-luciferase system
Li, S., Ruan, Z., Zhang, H., & Xu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113111 · Cited by 70
Role of Calixarene in Chemotherapy Delivery Strategies
Basilotta, R., Mannino, D., Filippone, A., Casili, G., Prestifilippo, A., Colarossi, L., Raciti, G., Esposito, E., & Campolo, M. (2021) · Molecules · doi:10.3390/molecules26133963 · Cited by 67
Azide‐Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy
Sun, J., Liu, Z., Yao, H., Zhang, H., Zheng, M., Shen, N., Cheng, J., Tang, Z., & Chen, X. (2023) · Advanced Materials · doi:10.1002/adma.202207733 · Cited by 72
Advanced targeted nanomedicine
Arachchige, M. C. M., Reshetnyak, Y. K., & Andreev, O. A. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.009 · Cited by 73
Targeting Notch to overcome radiation resistance
Yahyanejad, S., Theys, J., & Vooijs, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6714 · Cited by 79
Shen, Z., Prasai, B., Nakamura, Y., Kobayashi, H., Jackson, M. S., & McCarley, R. L. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01094 · Cited by 72
Lucien, F., Pelletier, P.-P., Lavoie, R. R., Lacroix, J.-M., Roy, S., Parent, J.-L., Arsenault, D., Harper, K., & Dubois, C. M. (2017) · Nature Communications · doi:10.1038/ncomms15884 · Cited by 66
Brandhonneur, N., Hatahet, T., Amela‐Cortes, M., Molard, Y., Cordier, S., & Dollo, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.007 · Cited by 71
Nocentini, A., Trallori, E., Singh, S., Lomelino, C. L., Bartolucci, G., Mannelli, L. D. C., Ghelardini, C., McKENNA, R. V., Gratteri, P., & Supuran, C. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01504 · Cited by 67
Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells
Tang, K., Yu, Y., Zhu, L., Xu, P., Chen, J., Ma, J., Zhang, H., Fang, H., Sun, W., Zhou, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0932-1 · Cited by 67
Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions
Busk, M., Overgaard, J., & Horsman, M. R. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.05.003 · Cited by 70
Li, H., Peng, C., Zhu, C., Nie, S., Qian, X., Shi, Z., Shi, M., Yan, L., Ding, X., Zhang, S., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01016-6 · Cited by 76
Enamine N -Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents
Kang, D., Cheung, S. T., Wong-Rolle, A., & Kim, J. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01586 · Cited by 69
Drug delivery strategy in hepatocellular carcinoma therapy
Yang, S., Cai, C., Wang, H., Ma, X., Shao, A., Sheng, J., & Yu, C. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00796-x · Cited by 70
A Hierarchical Mechanotransduction System: From Macro to Micro
Cao, R. Y., Tian, H., Tian, Y., & Fu, X. (2023) · Advanced Science · doi:10.1002/advs.202302327 · Cited by 74
Cázares-Körner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O’Connor, L. J., Olcina, M. M., Christlieb, M., Conway, S. J., & Hammond, E. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4001537 · Cited by 73
Wang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O., & Wilson, W. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2296 · Cited by 69
Self-citationMedical Applications of Isotope Metallomics
Albarède, F., Télouk, P., & Balter, V. (2017) · Reviews in Mineralogy and Geochemistry · doi:10.2138/rmg.2017.82.20 · Cited by 71
Ultrasound beam steering of oxygen nanobubbles for enhanced bladder cancer therapy
Bhandari, P. N., Novikova, G., Goergen, C. J., & Irudayaraj, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20363-8 · Cited by 72
A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2
Lee, H. R., Leslie, F., & Azarin, S. M. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0106-7 · Cited by 71
Geng, B., Yan, L., Zhu, Y., Shi, W., Wang, H., Mao, J., Ren, L., Zhang, J., Tian, Y., Gao, F., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202154 · Cited by 64
Zhang, L., Sun, J., Huang, W., Zhang, S., Deng, X., & Gao, W. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10188 · Cited by 67
Yang, F., Zhou, L., Wang, D., Wang, Z., & Huang, Q. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.051 · Cited by 67
Calpains and cancer: Friends or enemies?
Moretti, D., Bello, B. D., Allavena, G., & Maellaro, E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.09.018 · Cited by 70
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.